OmniAb Inc (NASDAQ:OABI) saw its shares climb 7.6% in premarket trading on Monday after the company disclosed a senior leadership change designed to support its screening technology and commercial efforts.
The biotechnology company said it had named Amechi Nwachuku to a newly-created position, Executive Vice President and Chief Operating Officer. In this role, Nwachuku will be responsible for overseeing strategy, operations and the commercial development of xPloration, OmniAb's single B-cell screening platform.
Nwachuku arrives with over 25 years of experience in life sciences tools businesses. His most recent role was Vice President of Global Commercial Genetic Sciences at Thermo Fisher Scientific. Prior positions include Senior Vice President, Global Commercial, SCIEX at Danaher Corporation, along with senior roles at Beckman Coulter Diagnostics, Johnson & Johnson Diabetes Care, and Bayer. He holds a Bachelor of Science in Chemical Engineering and an MBA from MIT.
OmniAb described its core business as providing discovery research technology for therapeutic development, with a licensing model centered on antibody discovery technology. The company said that this licensing business continues to perform strongly and now includes a growing portfolio of programs that carry milestone and royalty payments.
The xPloration platform is presented by the company as a high-throughput screening capability intended to support drug discovery campaigns. OmniAb stated that the platform is meant to complement its existing licensing operations and to create further revenue opportunities for the company.
Matt Foehr, President and Chief Executive Officer of OmniAb, said Nwachuku's experience would strengthen the executive management team and help capitalize on market opportunities for the xPloration platform.
The appointment and accompanying statement from management were followed by the premarket share gain. The company's public description emphasizes licensing and milestone- and royalty-bearing programs as central drivers of performance, while the newly announced role is focused on strategy, operations and commercial development tied to the xPloration offering.
Market context and company positioning
OmniAb's announcement links a strategic hire to the commercial rollout of a screening platform intended to broaden revenue sources beyond its established licensing business. The company highlighted the continuing strength of its licensing efforts and the expansion of programs that generate milestone and royalty income.
Details on execution timelines, market uptake of the xPloration platform, and financial impact were not provided in the company disclosure.